Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131085) titled 'QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)' on Aug. 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Anhui Provincial Hospital

Condition: MDS AML

Intervention: Drug: Allogeneic TCR-enhanced ?d T cell(QH101) Drug: Fludarabine (FLU)

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: August 15, 2025

Target Sample Size: 9

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07131085

P...